Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: anagnostopoulos i. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Oertel SH, et al. Among authors: anagnostopoulos i. Transplantation. 2000 Feb 15;69(3):430-2. doi: 10.1097/00007890-200002150-00021. Transplantation. 2000. PMID: 10706055
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Trappe RU, et al. Among authors: anagnostopoulos i. Transplantation. 2007 Dec 27;84(12):1708-12. doi: 10.1097/01.tp.0000295987.12996.19. Transplantation. 2007. PMID: 18165786
Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
Trappe R, Riess H, Anagnostopoulos I, Neuhaus R, Gärtner BC, Pohl H, Müller HP, Jonas S, Papp-Vary M, Oertel S. Trappe R, et al. Among authors: anagnostopoulos i. Ann Hematol. 2009 Feb;88(2):167-72. doi: 10.1007/s00277-008-0538-0. Epub 2008 Jul 18. Ann Hematol. 2009. PMID: 18636261 No abstract available.
270 results